Article Figures & Data
Figures
- Fig 1.
Histopathology of the invasive edge of the glioblastoma multiforme from patient 12 in the Table.
Top left, A, Low power, ×50, hematoxylin and eosin stain depicting tumor core (TC) and brain adjacent to tumor (BAT). Note the high cellularity of the core in the white matter, with invading cells spreading as far as the leptomeningeal space (LMS).
Top right, B, High power, ×400, of the BAT emphasizing perineuronal satellitosis—glioma cells around neuronal cell bodies (arrows).
Bottom left, C, Medium power, ×100, with a monoclonal antibody (NeuN) staining neurons.
Bottom right, D, High power, ×400, view of C highlighting immunoreactive neurons (arrows) surrounded by infiltrating tumor cells. These vacuolated neurons appear unhealthy, and therefore, are likely to contain less NAA. A healthy neuron is indicated for comparison (arrowhead).
- Fig 2.
Top, A and B, Segmented preoperative T1-weighted sagittal section for 2 patients, 15 and 5 in the Table, respectively. The red sulci and ventricle outline is the output of the tissue/CSF segmentation process. Patient A had a 41-cm3 grade III tumor, 3.0% of his brain volume, and 37% WBNAA deficit. Patient B had a 93-cm3 grade II tumor, 6.2% of his brain volume, but only half the WBNAA decline (∼20%).
Bottom, A′ and B′, Corresponding whole-head 1H-MR spectroscopy. The hatched regions indicate the peak-areas used to obtain QNAA of Equation (1). Note the overall similarity, indicating cross-sectional reproducibility, and good lipid suppression. Also note that, because localization relies on knowledge that NAA is found only in neuronal cells, it cannot quantify the brain’s contribution to metabolites also present in other tissue types (eg, choline, creatine, and so forth).
- Fig 3.
First, 2nd (median), and 3rd quartiles (box) and ±95% (whiskers) of WBNAA in the 17 controls, patients day of surgery (n = 17) and 1 day postsurgery (n = 14). Note that pre- and postsurgical WBNAA are significantly different from the controls, but not each other.
- Fig 4.
Scatter plot of WBNAA versus age for the patients before surgery and their age- and sex-matched controls. Note that the patients’ WBNAA deficit is significant (P < .0005), even after taking into account age (P = .007) and sex effects (P > .05).
- Fig 5.
First, 2nd (median), and 3rd quartiles (box) and ±95% (whiskers) of preoperative WBNAA in the 9 patients with low-grade tumors compared with their matched controls (left) and 8 patients with high-grade tumors compared with their matched controls (right). Note preoperative WBNAA was lower in patients with high-grade (8.3 ± 1.8 mmol/L) than in those with low-grade (10.0 ± 2.1 mmol/L) tumors.
Tables
Details of study participants
Patient No./Age (y)/Sex WBNAA (mM) Histology (Grade) Control Preoperation Postoperation Age (y)/Sex WBNAA (mM) 1/23/F 12.6 13.7 GGNC-DNT (I) 25/F 10.1 2/30/M 9.2 8.7 Mixed GN (II) 30/M 12.6 3/32/F 12.8 N/A Mixed GGNC (II) 31/F 11.4 4/32/F 9.9 9.2 DFA (II) 30/F 14.6 5/32/M 10.0 9.8 GGNC (II) 31/M 11.7 6/33/F 7.0 8.2 Mixed GN (II) 36/F 12.9 7/35/M 10.8 11.2 GBM (IV) 32/M 12.4 8/37/M 8.6 8.5 Mixed GN (II) 39/M 13.2 9/39/F 12.2 10.9 Mixed GN (II) 38/F 12.7 10/44/M 8.2 8.4 Mixed GGNC (II) 45/M 13.7 11/45/M 9.9 8.5 Anaplastic Mixed GN (III) 46/M 14.0 12/49/F 9.5 10.3 GBM (IV) 48/F 12.5 13/55/M 8.5 10.6 Anaplastic mixed GN (III) 55/M 13.1 14/57/M 7.4 6.7 GBM (IV) 60/M 15.1 15/62/M 7.9 11.2 AO (III) 65/M 11.7 16/74/M 7.8 N/A GBM (IV) 75/M 10.7 17/79/F 4.8 N/A Anaplastic GGNC (III) 76/F 10.7 Avg (mean ± SD) 9.2 ± 2.1 9.7 ± 1.8 12.5 ± 1.4 Note.—N/A indicates biopsy only or insufficient data due to patient movement; GGNC, ganglioglioneurocytoma; DNT, dysembryoplastic neuroepithelial tumor; GN, glioneurocytoma; DFA, diffuse fibrillary astrocytoma; GBM, glioblastoma multiforme; AO, anaplastic oligodendroglioma.
